drugs
JAMA highlights CT bill to limit extreme drug price increases
A recent JAMA article highlights bills to reduce drug price increases across states, including Connecticut’s bill. The bills call for clawing back 80% of drug price increases over inflation plus 2% — a healthy profit that many industries would happily welcome. Other states also considering bills include Massachusetts, Maine, Washington, and Hawaii; more are expected…
Read MoreCTNJ: OP-ED | Drug Affordability Requires Limits On Price Gouging
Jay Gironimi has cystic fibrosis and he is grateful for the drugs that help him live. But he disagrees with the Epilepsy Foundation’s opinion piece that defends extreme drug price hikes. “While the drugs are saving lives today, the profit margins are slowly tanking the entire US healthcare system.” Read more
Read MoreResponse: Lobbyist uses seniors and people with disabilities to protect drug company profits
Reading William Smith’s CT Mirror opinion, I was worried that my state had passed draconian laws that were harming the health of seniors and people with disabilities. Thankfully, that isn’t the case. Our anti-discrimination laws are still in place and functioning. . . . True discrimination against seniors and people with disabilities happens every day…
Read MoreHUSKY COVID update – new enrollments lag, lots of money to providers, and telehealth is very popular
At Friday’s Medicaid Council meeting, we learned that while new HUSKY applications recovered last fall from its drop last spring, they fell again sharply this January and February. The reasons for the volatility during a serious recession are unclear. DSS focused on how HUSKY has responded to the COVID pandemic. Now covering over a million…
Read MoreOpinion: Innovation isn’t helpful if we can’t afford it
In today’s CT Mirror, Jay Gironimi rebuts an opinion supporting the pharmaceutical industry and explains how extreme drug prices are hurting patients. Jay is supporting the Governor’s bill to tax excessive drug price increases years after the companies have recovered their research costs. Jay has Cystic Fibrosis and needs 10-12 medications daily so he can…
Read MoreCTNJ Op-Ed – Drug Innovation Argument Cuts Both Ways
In his recent op-ed, John Burkhardt of Pfizer misses important points when he asserts that the governor’s proposed tax on excessive prescription drug price increases will harm innovation and jobs in Connecticut. He ignores that rising drug prices are making health insurance unaffordable. Overpriced drugs inhibit other innovation and job growth across Connecticut’s economy. He…
Read MoreState Partnership Plan losing money but still more expensive than average CT plan options
Download the report Connecticut’s most recent public health insurance option, the Partnership Plan 2.0, offers healthcare coverage to municipal employees. According to a new analysis by Brown & Brown Insurance, Partnership Plan premium increases have not kept up with costs. The very impressive analysis is based on Freedom of Information requests; very little information on…
Read MoreCTNJ: If The COVID Vaccine Is Free For Patients, Who Is Paying For It?
Federal law ensures the COVID vaccine will be provided to every American at no cost. So who is paying for it? Because it’s healthcare, the answer is complicated and we are all paying for it – mostly through taxes and a bit through our insurance premiums. Read more
Read MoreCTNJ: OP-ED | State Should Set Uniform, Public Standards For Rationing Health Care
Disparities in healthcare are not new in our state, but the pandemic has intensified the unfairness. The aged, people with disabilities, and communities of color have been especially hard hit by the virus and the recession. Unfortunately, a striking example of that increased unfairness is reflected in Connecticut hospitals’ policies for rationing scarce resources during…
Read MoreUnjustified price increases for seven drugs in 2019 cost US healthcare $1.2 billion, CT can remedy this
According to a report released today, in 2019 the US health system spent an extra $1.2 billion on price increases for seven drugs that were not supported by clinical evidence. Enbrel led this year’s list costing Americans $403 million extra for an 8.9% net price increase, after accounting for rebates. The Unsupported Price Increase report…
Read More